Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10055040 | 0.92 | FFAR1 (0.68) | PPARAFFAR1MRGPRX4AKR1C3 | |
| SCHEMBL15458722 | 0.89 | HIF1A (0.67) | PPARAFFAR1MRGPRX4NPC1RAB9A | |
| SCHEMBL21370437 | 0.89 | PPARA (1.00) | PPARAFFAR1POLBMRGPRX4MEN1 | |
| SCHEMBL2185809 | 0.87 | FFAR1 (0.70) | PPARAFFAR1MRGPRX4NPC1RAB9A | |
| SCHEMBL13802457 | 0.87 | MRGPRX4 (0.63) | PPARAFFAR1MRGPRX4NPC1RAB9A | |
| SCHEMBL6840198 | 0.85 | PPARA (0.60) | PPARAFFAR1POLBMRGPRX4ALDH1A1 | |
| SCHEMBL12581587 | 0.84 | MRGPRX4 (0.73) | PPARAFFAR1MRGPRX4NPC1RAB9A | |
| SCHEMBL14758954 | 0.84 | FFAR1 (0.70) | PPARAFFAR1MRGPRX4NPC1RAB9A | |
| SCHEMBL14950693 | 0.84 | PPARA (0.62) | PPARAFFAR1 | |
| SCHEMBL8742132 | 0.83 | PPARA (0.57) | PPARAFFAR1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342177-B1 | NOVEL POTASSIUM CHANNEL BLOCKERS | JAPAN TOBACCO INC (JP) | 2017-02-15 | — | — | EP | disclosed |
| US-9447033-B2 | Potassium channel blockers | JAPAN TOBACCO INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20150259282-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-9073834-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2015-07-07 | — | — | US | disclosed |
| US-20140221337-A1 | Potassium Channel Blockers | XENTION LIMITED (GB) | 2014-08-07 | — | — | US | disclosed |
| US-8673901-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2014-03-18 | — | — | US | disclosed |
| EP-2342177-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | Xention Limited (GB) | 2011-07-13 | — | — | EP | disclosed |
| US-20100087428-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
| WO-2010023448-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS | XENTION LIMITED (GB) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221337-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | PPARA 4205/4885FFAR1 1688/4885POLB 4531/4885 |
| US-20100087428-A1 | Novel Potassium Channel Blockers | HCN4, SCN2B, KCNH2 | PPARA 1367/4885FFAR1 209/4885POLB 4553/4885 |
| US-20150259282-A1 | Potassium Channel Blockers | KCNJ2, KCNH2, KCNB1 | PPARA 4205/4885FFAR1 1688/4885POLB 4531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.